Chimera Biotec Awarded Grant to Support Ultra Sensitive Efficacy Testing of an Oral and Nasal Vaccine Delivery Platform.

Dortmund, Germany – 29th May, 2015 — Chimera Biotec GmbH, a specialist in ultra sensitive immunoassay development has received a significant project grant as part of a consortium looking to establish cold-chain independent virosome-based vaccine candidates.

 

Read the full press release here :

Press release ChimeraBiotec-MACIVIVA